Allergy

Blepharitis

COVID-19

Cataract

Comanagement

Comprehensive Eye Exams

Conjunctivitis

Contact Lenses

Cornea

Diabetic Eye Disease

Dry Eye

Geographic Atrophy

Glasses

Glaucoma

LASIK

Lens Technology

Lid and Lash

Myopia

Nutrition

Ocular Surface Disease

Optic Relief

Patient Care

Pediatrics

Presbyopia

Ptosis

Refractive Surgery

Retina

Technology

Therapeutic Cataract & Refractive

News

All News

Practice Management

Media

All Videos

Expert Interviews

Podcasts

Medical World News

Viewpoints

Insights

Case Based Roundtable Series

Case Studies

Case of the Quarter

Practice Ownership

Rapid Readout

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Conference Recaps

Blog

Publications

Digital Edition

Supplements And Featured Publications

iTech

Partners

Resources

Job Board

Subscribe

Articles

The generic formulation references Pred Forte, which is trademarked by Allergan.

FDA approves Amneal formulation of prednisolone acetate ophthalmic solution 1%

The report highlights clinical successes, innovation, research, and patient outcomes.

EyeCare Partners releases Quality and Outcomes Report, highlights optometric successes

The Vision Lab Choice Act of 2025, S 1716 was introduced to the US Senate floor on May 12.

VBM reform efforts continue with latest bill introduction

Incorporating peripheral OCTs into your practice provides valuable insights which may alter your clinical diagnosis.

Taking your OCT outside of the posterior pole

Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

Advertise

About Us

Editorial

Contact Us

Terms & Conditions

Privacy

Do not sell my Information

Optometry Times – Clinical News & Expert Optometrist Insights

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Myopia- Management

1rem

Authors

Private practice eye care providers’ ability to immediately administer antibiotic eye drops or have them overnighted to the patient is a giant step forward for practice and patient.

Fortified antibiotic advance improves corneal infection treatment paradigm

Brian Shafer, MD, discussed Fortisite and the ability to treat corneal ulcers at the 2023 ASCRS annual meeting in San Diego.

ASCRS 2023: Fortisite for corneal ulcers

Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.

CCS 2025: Clinical pearls and forward thinking are the key to success in myopia management

 continues to gain momentum in clinical optometry, and at the Collaborative Care Symposium, Erin Tomiyama, OD, PhD, FAAO, offered actionable advice and perspective for practitioners ready to refine their approach. This session, which Tomiyama co-presented with Mark Bullimore, OD, PhD, and Prethy Rao, MD, emphasized the importance of early intervention, lifestyle-informed treatment planning, and growing opportunities in the field.

Practical guidance for treatment selection

Tomiyama stressed that choosing the right myopia management modality requires an individualized approach. Factors such as patient age, rate of progression, lifestyle, and even parental familiarity with certain treatments all play into decision-making.

“For kids who enjoy water sports, orthokeratology (ortho-K) works really well—they get clear vision without needing to wear lenses in the water,” she explained. “Sometimes parents are more comfortable with treatments they’ve used themselves, which can improve compliance.”

Initial treatment may begin with atropine drops for younger children not ready for contact lenses. As patients mature and seek more independence, transitioning to soft multifocal lenses or ortho-K becomes feasible. Regardless of modality, frequent follow-ups allow optometrists to monitor compliance and treatment efficacy, making adjustments as needed.

Tomiyama expressed excitement about the potential introduction of FDA-approved low-dose atropine and myopia control spectacle lenses in the US. “Spectacles are part of our daily toolkit, and their arrival will help more practitioners feel confident offering myopia management,” she said. “It could broaden access significantly.”

FDA regulation would also reduce variability in compounded atropine formulations, offering more consistency for both clinicians and families.

Artificial intelligence is expected to play a larger role in myopia management, from identifying ideal candidates for specific therapies to tracking progression. “A quick AI-generated summary could save time and support faster clinical decision-making,” Tomiyama noted.

Tomiyama closed with a call to action: “Just practice myopia management. Get started and grow your confidence. We’re shaping long-term outcomes—starting in childhood.”

A new handheld device developed by University of Missouri – St Louis (UMSL) researchers works to detect and treat amblyopia early and utilizes the Quantitative 3 Dot (Q3D) Test to identify visual suppression.

 The device was developed by Curators’ Distinguished Teaching Professor Carl Bassi and research collaborators Michael Howe and Wayne Garver and has been licensed by Forus Health, according to a news release.

“I really do think it's going to be something that's going to help a lot of people,” Bassi said in the release. “I do think it can make a difference in the world.”

He stated in the release that he first came up with the idea for the device in the early 1990s, having just joined the UMSL faculty, while examining the vision of patients with Alzheimer disease. Bassi and his colleagues were modifying existing pediatric techniques in order to gauge binocular function, with one of the main screening tests being the Worth Four Dot Test.

“The problem is it's not quantitative,” Bassi said in the release. “It just gives you this gross kind of yes or no, and you have to have a severe problem before you're able to pick anything up with that. My idea very early on was to try to change the intensity of these lights independently. We had to wait for a long time until technology kind of caught up with doing what we wanted to do because it took the development of not only LED lights but super bright LED lights that were needed to do the test right.”

By being able to alter the intensity of these lights, the researchers have been able to detect vision suppression associated with amblyopia much soon than previous methods allowed.

Then, in 2014, they won a $50,000 FastTrack award from the University of Missouri System to create working prototypes for the device. After being studied at the UMSL Eye Care clinic, the Q3D device was involved in a clinical trial with more than 300 patients enrolled at the Cardinal Glennon Children’s Hospital, led by Oscar A Cruz, MD, and Bradley Davitt, MD. Trial results demonstrated that Q3D can be used on patients as young as 3 years and is a significantly more sensitive predictor of visual suppression when compared with current methods. Specifically, Q3D detected 4 times the number of impairments in patients with amblyopia as the Worth Four Dot Test.

"At Forus Health, our mission has always been to enable early, equitable, and impactful eye care,” said K. Chandrasekhar, the founder and CEO of Forus Health, in the release. “This commitment drives every innovation we pursue and every partnership we form, as we strive to make advanced eye care accessible to all, regardless of geography or socioeconomic status. Licensing the Q3D technology aligns perfectly with that vision. It represents a significant step forward in our ongoing efforts to equip clinicians with cutting-edge tools that enhance diagnostic accuracy and patient outcomes. By bringing a more sensitive and accessible diagnostic tool for amblyopia into the hands of clinicians, we have the opportunity to change the trajectory of vision outcomes for millions of children worldwide.

“We are proud to collaborate with the team at UMSL to take this innovation from lab to life, transforming early detection into early intervention."

Q3D diagnostic testing device developed at UMSL allows for earlier detection, treatment of amblyopia or “lazy eye.” News release. University of Missouri – St Louis. June 4, 2025. Accessed June 6, 2025.

The device was developed by Curators’ Distinguished Teaching Professor Carl Bassi and research collaborators Michael Howe and Wayne Garver of the University of Missouri – St Louis.

Researchers develop handheld device to improve early detection, treatment of amblyopia 

This quiz accompanies THIS article from our December issue

c. One-third eye width, canthus to canthus

d. One-third eye fissure opening vertically

Quiz: Know the ocular effects of eyelash growth serums

Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.

CCS 2025: Tackling the complexities of glaucoma management

Alongside Tanner Ferguson, MD, Mitch Ibach, OD, FAAO, focused on glaucoma management and minimally invasive glaucoma surgery (MIGS) in a Collaborative Care Symposium (CCS) 2025 presentation. Ibach emphasized interventional approaches and collaborative care between optometrists and ophthalmologists. Ibach highlights 4 primary modalities for lowering intraocular pressure (IOP):

Drug delivery devices (2 FDA-approved options)

Laser trabeculoplasty (specifically direct selective laser trabeculoplasty or DSLT)

Glaucoma surgeries, including MIGS and incisional surgeries like tubes and traps

A key theme is the complexity of glaucoma treatment, with Ibach noting there's no single "magic bullet" cure. Patients often experience a dynamic treatment journey, cycling through different interventions like selective laser trabeculoplasty, medication adjustments, and surgical procedures. The presentation strongly emphasizes collaborative care, with several critical recommendations:

Establish clear communication between referring doctors and surgical centers

Set explicit expectations about patient management post-intervention

Understand the interplay of various treatment technologies

Ibach passionately advocates for professional collaboration, highlighting that optometrists and ophthalmologists have complementary skills. Although optometrists don't perform intraocular surgeries, and ophthalmologists may not want to manage routine vision care, they can work together effectively to provide comprehensive patient care. A significant pearl of wisdom is not to miss opportunities for minimally invasive glaucoma surgery, particularly during cataract surgery. This moment represents a critical intervention point where patients can simultaneously address cataract removal and glaucoma management. The ultimate goals outlined include lowering eye pressure, reducing medication burden, minimizing ocular surface disease, and improving patient quality of life.

Ibach's approach emphasizes flexibility, continuous learning, and a commitment to patient-first care, viewing glaucoma management as a collaborative, evolving journey rather than a one-time intervention.

Conference

Bausch + Lomb has launched its Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops in the US.

 Both drops will be available in most national retailers, including Walmart, Target, CVS, Walgreens, and Amazon, according to a news release.

The preservative-free, contact lens-friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

"Blink Nourish and Blink Boost deliver the same science-backed, long-lasting relief that consumers have come to rely on from our other Blink eye drop products,” said John Ferris, president, Consumer, Bausch + Lomb. “These preservative-free options provide sufferers of dry eyes – especially those with sensitive eyes – with even more ways to achieve relief."

, vitamin C, magnesium, and amino acids that assist the drop in replenishing and rebalancing the tear film. The drop’s pH-balanced composition also hydrates the eye with the active ingredient glycerin, in addition to containing hyaluronan, a moisturizer naturally found in tears, and trehalose in order to promote tear film stability.

Blink Boost also contains a combination of ingredients that are naturally inspired and included in the drop’s formulation in reference to the Tear Film and Ocular Surface Society’s DEWS II report. Some of these ingredients include HA and an electrolyte – components of natural tears – and an antioxidant, which protects HA from free radicals, the release stated. The formula is also pH balanced to match healthy tears.

“These new preservative-free eye drops deliver a blend of ingredients that not only hydrate but also promote a healthy ocular surface,” said Gina Wesley, OD, of Complete Eye Care in Medina, Minnesota, in the release. “My patients with sensitivities now have 2 new options from the Blink eye drop portfolio to help address their dry eye symptoms.”

The launch of the drops by Bausch + Lomb follows on the heels of the company’s launch of LUMIFY Preservative Free redness reliever eye drops in the US. The first and only preservation-free OTC eye drops contain low-dose brimonidine tartrate 0.025% that works to relieve redness of the eye due to minor eye irritations.

Bausch + Lomb launches Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops in the United States. News release. Bausch + Lomb. June 4, 2025. Accessed June 4, 2025.

J Joy. Bausch + Lomb launches LUMIFY Preservative Free redness reliever eye drops in the US. 

https://www.optometrytimes.com/view/bausch-lomb-launches-lumify-preservative-free-redness-reliever-eye-drops-in-us

Both preservative-free, contact lens-friendly drops will be available in most national retailers.

Bausch + Lomb launch Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops in the US for dry eye

HOYA Vision Care recently announced its acquisition of Canadian distributor Centennial Optical.

 Centennial Optical distributes ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories.

“We continuously seek new opportunities to deliver greater value and drive innovation,” said Steven Haifawi, president of HOYA Vision Care Canada, in a press release. “This strategic investment expands both our companies’ capabilities and enhances our competitive positions in the market while strengthening our partnerships with customers across Canada.”

HOYA Vision Care has a presence in over 50 countries, is seen as a leader in myopia management and has a proven track record in advanced lens design, high-performance photochromic technologies, and high-quality AR coatings.

HOYA’s acquisition of Centennial Optical will allow the companies to better serve the Canadian market by leveraging HOYA’s resources and technologies, now adding Centennial Optical’s foundation.

“We carefully considered the future of our business, our customers, and our employees,” said Allen Nightingale, president of Centennial Optical, in a press release. Nightingale said HOYA’s industry leadership was only part of what stood out to the company, citing HOYA’s alignment with Centennial Optical’s culture, values, and mission.

“HOYA shares our commitment to innovation, integrity, and customer-focused service, which made them the right partner for Centennial’s next chapter.”

1. HOYA Vision Care Acquires Centennial Optical | HOYA Vision Care. HOYA Vision Care. Published 2025. Accessed June 3, 2025. https://www.hoyavision.com/en-us/newsroom/hoya-in-the-news/news-folder/hoya-vision-care-acquires-centennial-optical/

This strategic investment will allow both companies to better serve the Canadian market.

Brian Shafer, MD

Articles

Latest Updated Articles